MD-ZEROFOX
26.4.2021 15:02:10 CEST | Business Wire | Press release
ZeroFOX , leader in External Threat Intelligence and Protection, today announced the launch of the ZeroFOX Global Partner Program , a strategic pivot to a partner-first strategy. This move significantly increases ZeroFOX’s investment in partner enablement and commitment to conducting all business with and through their full partner ecosystem.
Another leap forward following the company’s significant expansion of cyber threat intelligence capabilities and addition of three 24/7 global security operations centers (SOCs), ZeroFOX’s partner-first strategy will accelerate capabilities for new and existing customers. Supported by a three-tier structure with escalating benefits, including graduating sales incentives, white glove support and marketing development funds, the Global Partner Program also offers a comprehensive go-to-market toolbox to meet the on-demand needs of a global salesforce. Specialized, entrepreneurial partner organizations with access to strategic geographic and vertical markets will be supported through an incubator program that incentivizes successful marketing initiatives, achieving training goals and overall business velocity.
Gartner forecasts that worldwide IT spending will increase 6.2% this year compared to last, reaching $3.9 trillion. Amid this tech growth, businesses are re-examining their cybersecurity approach. In fact, over half (55%) of tech and security executives plan to increase their cyber budgets this year, according to a recent PwC survey . With remote work and digital dependency – including an influx in social media use driven by the pandemic – contributing directly to this rise in attacks, it’s essential that the cybersecurity industry works to drive resiliency across markets.
“Our partners rely on ZeroFOX’s unmatched pace of innovation and commitment to delivering the world’s strongest external threat intelligence service. Together, we have put ourselves in a position to deliver unrivaled protection, intelligence, and disruption capabilities to all of our customers,” said James C. Foster, CEO of ZeroFOX . “Furthermore, our customers appreciate that as a partner-first organization, we invest in differentiated partner solutions. Our AI platform is a true difference maker for our partners and customers alike.”
With ZeroFOX’s Global Partner Program, partners and MSSPs seeking to increase customer value will be provided a rich set of professional services capabilities that ultimately enrich their core offering. To lead the charge, ZeroFOX has hired a full global partnerships team of channel veterans, including a dedicated team of channel partner directors, solution engineers and marketing experts, led by ZeroFOX Vice President of Global Partnerships, Brian Costello.
“ZeroFOX’s investment in enabling partners through sales, marketing, and technical expertise means that our partners can go-to-market faster, drive more demand, and secure more sustainable sources of revenue,” said Brian Costello, Vice President of Global Partnerships at ZeroFOX . “Both on-demand and white glove programs mean partners can confidently project the value that ZeroFOX brings to their portfolio.”
ZeroFOX expects to double partner contribution to the business this year, already acquiring the company’s largest customer in company history through a partner-based contract. Partners continue to broaden ZeroFOX’s capabilities into several verticals targeted widely by cyber criminals, including healthcare and financial services, and extend the company’s geographic footprint and expansion in EMEA, APAC and LATAM.
“ZeroFOX’s ability to bridge social, mobile, surface, and deep and dark web environments delivers a powerful digital risk protection solution in line with Exclusive Networks UK’s ethos of enabling our Partners to differentiate themselves through innovation and addressing the new challenges faced by end users,” said Mark Parr, Director of Strategic Vendors at Exclusive Networks UK . “Our partnership with ZeroFOX has helped drive growth and uncover new opportunities alongside our diverse range of partners. Furthermore, ZeroFOX's integrations with several of our existing technologies results in the creation of comprehensive and scalable solutions to be adopted by our broad partner base. The synergy between Exclusive Networks UK and ZeroFOX extends beyond technology with both organizations leading with a ‘can do’ approach and continually striving to innovate. This makes working together a natural choice.”
To find out more information about ZeroFOX, please visit our website at www.zerofox.com .
About ZeroFOX – ZeroFOX provides enterprises protection, intelligence and disruption to dismantle external threats to brands, people, assets and data across the public attack surface in one, comprehensive platform. With complete global coverage across the surface, deep and dark web and an Intel-backed artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005428/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom